• About us
• Contact

Advertisement

Product › Details

Chimeric Antigen Receptor T-Cell therapy (CAR-T therapy)

	Next higher product group	cancer immunotherapy (immuno-oncology, I-O)
	Status	2012-10-06

Record changed: 2023-07-10

Advertisement

More documents for Chimeric Antigen Receptor T-Cell therapy (CAR-T therapy)

• [1] T-Curx GmbH. (10/6/22). "Press Release: T-Curx GmbH, a German CAR-T Cell Biotech Spin-Off from University of Würzburg, Appoints Ulf Grawunder as CEO". Würzburg....
• [2] T-Curx GmbH. (9/15/22). "Press Release: Caroline Burger, PhD, Appointed as T-Curx' Global Head Business Development". Würzburg....
• [3] Autolus Therapeutics Ltd.. (9/18/17). "Press Release: Autolus Announces Initiation of the AMELIA and ALEXANDER Studies for AUTO3. Phase I/II Studies in Paediatric ALL and DLBCL"....
• [4] Autolus Therapeutics Ltd.. (9/18/17). "Press Release: Autolus Announces First-Dose Cohort Completed in APRIL Study of AUTO2. A Phase I/II Study in Patients with Multiple Myeloma"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.